Madrigal PharmaceuticalsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Madrigal Pharmaceuticals (MDGL) reported revenue of $364.00M in Q2 2026.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
Madrigal PharmaceuticalsRezdiffra (resmetirom): first FDA-approved MASH treatment (March 2024, thyroid hormone receptor-beta agonist). Q1 2026 net sales $311M (+127% YoY), 42,250+ patients on therapy. Competes with GLP-1 in MASH.
Madrigal Pharmaceuticals (MDGL) is a Biotechnology company. Rezdiffra (resmetirom): first FDA-approved MASH treatment (March 2024, thyroid hormone receptor-beta agonist). Q1 2026 net sales $311M (+127% YoY), 42,250+ patients on therapy. Competes with GLP-1 in MASH. It was founded in 2011, is headquartered in West Conshohocken, PA and employs about 290 people.
Track Madrigal Pharmaceuticals's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 21, 2026.
Sterling groups Madrigal Pharmaceuticals in the GLP-1 sector, alongside Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE), Amgen (AMGN), Roche (RHHBY) and AstraZeneca (AZN).
If you are researching Madrigal Pharmaceuticals, also look at Eli Lilly (LLY), Novo Nordisk (NVO) and Pfizer (PFE). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.